Brenzavvy vs Farxiga for T2D; PFAS in Seafood; 100 Deaths Linked to GLP-1 Drugs?
(MedPage Today) -- Bexagliflozin (Brenzavvy) and dapagliflozin (Farxiga) induced similar HbA1c reductions over 24 weeks in a head-to-head phase III trial of the SGLT2 inhibitors in Chinese adults with type 2 diabetes on metformin. (Journal of Diabetes... (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - April 16, 2024 Category: Endocrinology Source Type: news
SGLT2i Better Than Diuretic for Early Decongestion in Acute Heart Failure?
(MedPage Today) -- Starting dapagliflozin (Farxiga) early during acute heart failure hospitalization didn't boost decongestion, although it appeared to spare loop diuretic doses and increase diuresis compared with usual care, the DICTATE-AHF trial... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - April 2, 2024 Category: Cardiology Source Type: news
Dapagliflozin Cuts Cardiovascular Events in Patients With Heart Failure, T2D
WEDNESDAY, Dec. 27, 2023 -- For patients with heart failure and type 2 diabetes (T2D), dapagliflozin does not reduce urinary albumin-to-creatinine ratio (UACR) but does reduce some cardiovascular events, according to a study published online Nov. 27... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 27, 2023 Category: Pharmaceuticals Source Type: news
Potential Dapagliflozin Benefit Post-MI Is Not a'Mandate'Potential Dapagliflozin Benefit Post-MI Is Not a'Mandate '
A registry trial of SGLT-2 inhibition in low-risk patients after an MI showed some benefit in preventing future events, but a larger study would be warranted to further validate the signal.MDedge News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 12, 2023 Category: Cardiology Tags: Cardiology News Source Type: news
Will Kidney Disease Patients Finally Receive New Drug Class? Will Kidney Disease Patients Finally Receive New Drug Class?
Dapagliflozin became the first SGLT2 inhibitor approved for CKD alone just over 2 years ago, but uptake has lagged. Could a similar label gain for empagliflozin, plus a new recommendation, spark change?Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 19, 2023 Category: Consumer Health News Tags: Nephrology News Source Type: news
Glenmark launches triple-drug combo for type 2 diabetes
Glenmark Pharmaceuticals has launched a triple-fixed-dose combination drug called Zita for the treatment of Type 2 diabetes. The drug, which combines Teneligliptin, Dapagliflozin, and Metformin, is priced at Rs 14 per tablet and aims to improve glycemic control in diabetic patients. The medication is expected to lower the daily cost of therapy by 30%, making it more affordable for patients. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 18, 2023 Category: Pharmaceuticals Source Type: news
Farxiga Cuts A1c in Pediatric Diabetes; Late-Stage CAH Win; At-Home Menopause Test
(MedPage Today) -- Dapagliflozin (Farxiga) lowered HbA1c by 1.03 percentage points more than placebo in children and adolescents with type 2 diabetes, while saxagliptin (Onglyza) showed no significant reduction versus placebo, the phase III T2NOW... (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - October 10, 2023 Category: Endocrinology Source Type: news
SGLT2i in Acute Heart Failure, The Earlier The Better? SGLT2i in Acute Heart Failure, The Earlier The Better?
Ileana Pi ña interviews Zachary Cox, PharmD, about the DICTATE-AHF trial on the initiation of the SGLT2 inhibitor, dapagliflozin, early in acute heart failure decompensation.theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - September 20, 2023 Category: Cardiology Tags: Cardiology Commentary Source Type: news
SGLT2i Safety in Acute Heart Failure Confirmed by New Data SGLT2i Safety in Acute Heart Failure Confirmed by New Data
Results of the DICTATE-AHF randomized trial that tested starting dapagliflozin for patients hospitalized with acute heart failure confirmed the safety and benefit of this guideline-directed strategy.Medscape Medical News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - September 6, 2023 Category: Internal Medicine Tags: Cardiology News Source Type: news
AstraZeneca gets GCGI approval to import heart failure drug
AstraZeneca Pharma India on Monday said it has received approval from the Drugs Controller General of India to import heart failure treatment drug Dapagliflozin tablets. The company has received permission from the DCGI to import pharmaceutical formulations of a new drug for sale, the drug firm said in a regulatory filing. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - July 24, 2023 Category: Pharmaceuticals Source Type: news
Dapagliflozin Matches Non-Loop Diuretic for AHF Congestion Dapagliflozin Matches Non-Loop Diuretic for AHF Congestion
The SGLT2 inhibitor didn ' t relieve congestion more effectively than a ' thiazide-like ' diuretic when added to furosemide in loop-diuretic –resistant patients with acute heart failure.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - June 6, 2023 Category: Cardiology Tags: Cardiology News Source Type: news
Farxiga's Decongestion Flop; Benefit of Strong Legs; 2,500-Mile Heart Transport
(MedPage Today) -- Patients resistant to the loop diuretic furosemide did not find greater decongestive relief from dapagliflozin (Farxiga) than metolazone in a small trial. (European Heart Journal)
Longer time spent in body weight time in target... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - May 23, 2023 Category: Cardiology Source Type: news
Breakthrough daily diabetes tablet to treat all British heart failure sufferers secures NHS approval
All British heart failure sufferers (file photo) will now be eligible for a breakthrough daily tablet, dapagliflozin, that dramatically reduces symptoms and boosts survival chances. (Source: the Mail online | Health)
Source: the Mail online | Health - May 20, 2023 Category: Consumer Health News Source Type: news
Farxiga OK'd for All EF; Older Donor Hearts; Cardiologist Arrested for Deaths
(MedPage Today) -- FDA gave expanded approval to the SGLT-2 inhibitor dapagliflozin (Farxiga) for preventing cardiovascular death, heart failure hospitalization, and urgent heart failure visits in all patients with heart failure regardless of ejection... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - May 10, 2023 Category: Cardiology Source Type: news
Farxiga Extended in the US to Reduce Risk of Cardiovascular Death and Hospitalisation for Heart Failure to a Broader Range of Patients
May 9, 2023 -- AstraZeneca’s Farxiga (dapagliflozin) has been approved in the US to reduce the risk of cardiovascular (CV) death, hospitalisation for heart failure (hHF) and urgent heart failure (HF) visits in adults with HF. The approval by... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 9, 2023 Category: Drugs & Pharmacology Source Type: news
